OncoMatch/Clinical Trials/NCT06485713
Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC
Is NCT06485713 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including trifluridine/tipiracil combined with fufuquitinib and fufuquitinib for metastatic colorectal cancer.
Treatment: trifluridine/tipiracil combined with fufuquitinib · fufuquitinib · Trifluridine/tipiracil — To evaluate the efficacy and safety of trifluridine/tipiracil combined with fufuquitinib versus trifluridine/tipiracil and fufuquitinib in patients with unresectable metastatic colorectal cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Colorectal Cancer
Disease stage
Metastatic disease required
advanced colorectal adenocarcinoma; At least 1 measurable lesion was present according to RECIST1.1 criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: standard first- and second-line treatment
who had failed standard first - and second-line treatment
Lab requirements
Blood counts
Hemoglobin ≥90g/L; Absolute count of neutrophils (ANC) ≥1.5×10^9/L; Platelet ≥100×10^9/L
Kidney function
Serum creatinine (CR) <1.5 ULN or creatinine clearance (CCR) ≥50ml/min
Liver function
ALT and AST ≤2.5 ULN; ALP ≤2.5 ULN (if liver metastases ≤5 ULN); Total bilirubin (TBIL) < 1.5 ULN
Cardiac function
Left ventricular ejection fraction (LVEF) ≥50%
Good organ function, laboratory tests meet the following criteria: Hemoglobin ≥90g/L; ANC ≥1.5×10^9/L; Platelet ≥100×10^9/L; ALT and AST ≤2.5 ULN; ALP ≤2.5 ULN (if liver metastases ≤5 ULN); Total bilirubin (TBIL) < 1.5 ULN; Serum creatinine (CR) <1.5 ULN or creatinine clearance (CCR) ≥50ml/min; Serum albumin ≥30g/L; INR, PT, APTT ≤1.5 ULN; TSH ≤ULN; LVEF ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06485713 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received standard first- and second-line treatment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages